PURPOSE: This study addressed whether age is prognostic for overall survival (OS) or progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: A total of 20,023 patients from 24 first-line clinical trials in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were analyzed. Primary age effects and interactions with age,sex, performance status (PS), and metastatic site were modeled using Cox proportional hazards stratified by treatment arm within study. RESULTS: Of total patients, 3,051 (15%) were age < or =50 years. Age was prognostic for both OS (P < .001)and PFS (P < .001), with U-shaped risk (i.e., highest risk was evident in youngest and oldest patients). Relative to patients of middle age, the youngest patients experienced 19% (95% CI, 7% to 33%) increased risk of death and 22% (95% CI, 10% to 35%) increased risk of progression. The oldest patients experienced 42% (95% CI, 31% to 54%) increased risk of death and 15% (95% CI, 7% to 24%) increased risk of progression or death. This relationship was more pronounced in the first year of follow-up. Age remained marginally significant for OS (P = .08) when adjusted forPS, sex, and presence of liver, lung, or peritoneal metastases, and age was significant in an adjusted model for PFS (P = .005). The age effect did not differ by site of metastatic disease, year of enrollment, type of therapy received, or biomarker mutational status. CONCLUSION: Younger and older age are associated with poorer OS and PFS among treated patients with mCRC. Younger and older patients may represent higher-risk populations, and additional studies are warranted.
PURPOSE: This study addressed whether age is prognostic for overall survival (OS) or progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: A total of 20,023 patients from 24 first-line clinical trials in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were analyzed. Primary age effects and interactions with age,sex, performance status (PS), and metastatic site were modeled using Cox proportional hazards stratified by treatment arm within study. RESULTS: Of total patients, 3,051 (15%) were age < or =50 years. Age was prognostic for both OS (P < .001)and PFS (P < .001), with U-shaped risk (i.e., highest risk was evident in youngest and oldest patients). Relative to patients of middle age, the youngest patients experienced 19% (95% CI, 7% to 33%) increased risk of death and 22% (95% CI, 10% to 35%) increased risk of progression. The oldest patients experienced 42% (95% CI, 31% to 54%) increased risk of death and 15% (95% CI, 7% to 24%) increased risk of progression or death. This relationship was more pronounced in the first year of follow-up. Age remained marginally significant for OS (P = .08) when adjusted forPS, sex, and presence of liver, lung, or peritoneal metastases, and age was significant in an adjusted model for PFS (P = .005). The age effect did not differ by site of metastatic disease, year of enrollment, type of therapy received, or biomarker mutational status. CONCLUSION: Younger and older age are associated with poorer OS and PFS among treated patients with mCRC. Younger and older patients may represent higher-risk populations, and additional studies are warranted.
Authors: Vera Simone Schellerer; Susanne Merkel; Silke Christiane Schumann; Anne Schlabrakowski; Thomas Förtsch; Claus Schildberg; Werner Hohenberger; Roland Siegfried Croner Journal: Int J Colorectal Dis Date: 2011-09-01 Impact factor: 2.571
Authors: Paul J Limburg; William S Harmsen; Helen H Chen; Steven Gallinger; Robert W Haile; John A Baron; Graham Casey; Michael O Woods; Stephen N Thibodeau; Noralane M Lindor Journal: Clin Gastroenterol Hepatol Date: 2010-11-05 Impact factor: 11.382
Authors: Gemma Gatta; Giulia Zigon; Riccardo Capocaccia; Jan Willem Coebergh; Emmanuel Desandes; Peter Kaatsch; Guido Pastore; Rafael Peris-Bonet; Charles A Stiller Journal: Eur J Cancer Date: 2009-02-21 Impact factor: 9.162
Authors: Lindsay A Renfro; Richard M Goldberg; Axel Grothey; Alberto Sobrero; Richard Adams; Matthew T Seymour; Volker Heinemann; Hans-Joachim Schmoll; Jean-Yves Douillard; Herbert Hurwitz; Charles S Fuchs; Eduardo Diaz-Rubio; Rainer Porschen; Christophe Tournigand; Benoist Chibaudel; Paulo M Hoff; Fairooz F Kabbinavar; Alfredo Falcone; Niall C Tebbutt; Cornelis J A Punt; J Randolph Hecht; John Souglakos; Carsten Bokemeyer; Eric Van Cutsem; Leonard Saltz; Aimery de Gramont; Daniel J Sargent Journal: J Clin Oncol Date: 2017-04-17 Impact factor: 44.544
Authors: Christopher H Lieu; Erica A Golemis; Ilya G Serebriiskii; Justin Newberg; Amanda Hemmerich; Caitlin Connelly; Wells A Messersmith; Cathy Eng; S Gail Eckhardt; Garrett Frampton; Matthew Cooke; Joshua E Meyer Journal: Clin Cancer Res Date: 2019-06-26 Impact factor: 12.531
Authors: Daniel Y Wang; Aaron P Thrift; Neda Zarrin-Khameh; Alexandra Wichmann; Georgina N Armstrong; Patricia A Thompson; Melissa L Bondy; Benjamin L Musher Journal: J Clin Gastroenterol Date: 2017-01 Impact factor: 3.062
Authors: Lindsay A Renfro; Fotios Loupakis; Richard A Adams; Matthew T Seymour; Volker Heinemann; Hans-Joachim Schmoll; Jean-Yves Douillard; Herbert Hurwitz; Charles S Fuchs; Eduardo Diaz-Rubio; Rainer Porschen; Christophe Tournigand; Benoist Chibaudel; Alfredo Falcone; Niall C Tebbutt; Cornelis J A Punt; J Randolph Hecht; Carsten Bokemeyer; Eric Van Cutsem; Richard M Goldberg; Leonard B Saltz; Aimery de Gramont; Daniel J Sargent; Heinz-Josef Lenz Journal: J Clin Oncol Date: 2015-10-26 Impact factor: 44.544